Drs. Melissa Barnett and Mile Brujic discuss how genetic testing for keratoconus may help catch refractive surgery candidates who may be at risk for developing keratoconus. They also discuss the future of genetic testing in today’s optometric practice. This is Part 2 of 2.
This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
This podcast has no credit associated with it.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Mile Brujic, OD, FAAO
Partner
Premier Vision Group
Bowling Green, OH
Melissa Barnett, OD, FAAO, FSLS, FBCLA
Principal Optometrist
University of California, Davis, Eye Center
Sacramento, CA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Mile Brujic, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Akorn, Alcon Vision, Allergan, Bausch + Lomb Health, Blephex, Contamac, CSEye, Eyevance, Horizon Therapeutics, Kala Pharmaceuticals, Novartis, Sun Pharmaceutical Industries, VMax Vision, and Zea Vision. Speaker’s Bureau: Allergan, Bausch + Lomb Health, Kala Pharmaceuticals, Novartis, Optovue, Sun Pharmaceutical Industries, and Zea Vision. Grant/Research Support: Contamac.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Azura, Bruder, Cooper Vision, Dompe, Everyday Contacts, EyeEco, Mojo Vision, Novartis, Ocusoft, Oyster Point, Percept, and Raayonnova. Advisory Board/Consultant: Visus Therapeutics. Advisory Board/Speaker's Bureau: AAB, Acculens, Allergan, Bausch + Lomb, Contamac, Gas Permeable Lens Institute, JJVC Vistakon, RVL Pharmaceuticals, Scleral Lense Education Society, Synergeyes, Tangible Science, Tarsus. Speaker's Bureau: BCLA, Science Based Health, Sjogren's Syndrom Foundation, and STAPLE Program.
The Evolve and The Fundingsland Group planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Orasis Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
